The Prognostic Value of Pretreatment Serum LDH at Diagnosis in Patients with Hodgkin Lymphoma
| International Journal of Medical Science |
| © 2023 by SSRG - IJMS Journal |
| Volume 10 Issue 6 |
| Year of Publication : 2023 |
| Authors : Firas Hussein |
10.14445/23939117/IJMS-V10I6P101
How to Cite?
Firas Hussein, "The Prognostic Value of Pretreatment Serum LDH at Diagnosis in Patients with Hodgkin Lymphoma," SSRG International Journal of Medical Science, vol. 10, no. 6, pp. 1-10, 2023. Crossref, https://doi.org/10.14445/23939117/IJMS-V10I6P101
Abstract:
Background: Lactate dehydrogenase (LDH) is a marker for lymphoma whose prognostic significance is well established for both indolent and aggressive non-Hodgkin lymphomas but has not been well studied in predicting prognosis in patients with Hodgkin lymphoma. This prompts us to study the prognostic value of LDH in Hodgkin Lymphoma. Aim of the study: We studied the correlation between pre–treatment serum LDH and prognosis (OS, PFS and mortality) in Hodgkin lymphoma patients in our center, Lattakia –Syria. Patients and Methods: This was a retrospective study conducted at University Tishreen Hospital in Lattakia City, Syria, over a period of five years. 208 patients were enrolled in the study. We analyzed recorded data from the patient's files: medical history, full physical examination, complete blood count, AMC, ALC, LMR, erythrocyte sedimentation rate, liver function tests, serum LDH, and serum Albumin. , histological type, radiological investigations, bone marrow biopsy, staging, spread of disease, Mediastinal bulky mass and international prognostic factors IPS. Patients or their guardians provided written informed consent to participate in the study. Then, we evaluated the prognostic value of pretreatment serum LDH in patients with Hodgkin's Disease through a study of overall survival (OS), progression–free survival rate (PFS) and rate of deaths. Results: Pre-treatment serum LDH of more than 480 u/ml is an important indicator of the severity of Hodgkin lymphoma. It is highly associated with advanced stage, presence of B symptoms, and bulky mediational mass. It is also highly correlated with bad international prognostic factors (IPS) of Hodgkin lymphoma. The independent prognostic factors in multivariate analysis were high pretreatment serum LDH and low LMR, which are strongly associated with poor prognosis for patients. Our study revealed that pretreatment serum LDH > 480 was associated with a decrease in OS rates (78.5%) versus (92.3%) in the LDH group ≤480 (p-value=0.004). It was also associated with a decrease in PFS rate (63.1%) versus( 81.1%) in the LDH group ≤480 ( p-value=0.005). We observed an increase in mortality rate in the LDH group > 480 (21.5%) versus (8.4%) in the LDH group ≤ 480 with a statistical difference (p-value=0.008). Conclusion: pretreatment serum LDH > 480 Un is an important indicator of the severity of Hodgkin lymphoma and an independent prognostic factor for (OS, PFS and mortality) rate.
Keywords:
LDH, Hodgkin lymphoma, Prognosis, PFS and OS.
References:
[1] Ferlay J, Bray F, Pisani P, et al (Eds). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press; 2004.
[Google Scholar]
[2] Punam Pahwa et al., “Ethnicity and Incidence of Hodgkin’s Lymphoma in Canadian Population,” BMC Cancer, vol. 9, no. 141, 2009.
[CrossRef] [Google Scholar] [Publisher Link]
[3] Lynny Yung, and David Linch, “Hodgkin’s lymphoma,” The Lancet, vol. 361, no. 9361, pp. 943-951, 2003.
[CrossRef] [Google Scholar] [Publisher Link]
[4] Kenneth A. Maclennan et al., “Relationship of Histopathologic Features to Survival and Relapse in Nodular Sclerosing Hodgkin’s Disease. A Study of 1659 Patients,” Cancer, vol. 64, no. 8, pp. 1686-1693, 1989.
[CrossRef] [Google Scholar] [Publisher Link]
[5] S Bodis et al., “Late Relapse in Early Stage Hodgkin’s Disease Patients Enrolled on European Organization for Research and Treatment of Cancer Protocols,” Journal of Clinical Oncology, vol. 11, no. 2, pp. 225-232, 1993.
[CrossRef] [Google Scholar] [Publisher Link]
[6] René-Olivier Casasnovas et al., “Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients with Classical Hodgkin's Lymphoma: A Study from the Groupe d'Etude des Lymphomes de l'Adulte,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1732-1740, 2007.
[CrossRef] [Google Scholar] [Publisher Link]
[7] Joseph M. Connors, “State-of-The-Art Therapeutics: Hodgkin’s Lymphoma,” Journal of Clinical Oncology, vol. 23, no. 26, pp. 6400-6408, 2005.
[CrossRef] [Google Scholar] [Publisher Link]
[8] Dirk Hasenclever et al., A Prognostic Score for Advanced Hodgkin’s Disease, New England Journal of Medicine, vol. 339, pp. 1506- 1514, 1998.
[CrossRef] [Google Scholar] [Publisher Link]
[9] Berk PD, Korenblat KM. Approach to the patient with jaundice or abnormal liver test results. Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 150.
[Google Scholar]
[10] John W. Sweetenham, “Treatment of Lymphoblastic Lymphoma in Adults,” Oncology, vol. 23, no. 12, pp. 1015-1020, 2009.
[Google Scholar] [Publisher Link]
[11] Steven H. Bernstein, and W. Richard Burack, “The Incidence, Natural History, Biology, and Treatment of Transformed Lymphomas,” Hematology Am Soc Hematol Educ Program, vol. 2009, no. 1, pp. 532–541 2009.
[CrossRef] [Google Scholar] [Publisher Link]
[12] John Kuruvilla, “Standard Therapy of Advanced Hodgkin Lymphoma,” Hematology Am Soc Hematol Educ Program, vol. 2009, no. 1, pp. 497-506, 2009.
[CrossRef] [Google Scholar] [Publisher Link]
[13] Charles M. Balch et al., “An Evidence-Based Staging System for Cutaneous Melanoma,” CA: A Cancer Journal for Clinicians, vol. 54, no. 3, pp. 131-149, 2004.
[CrossRef] [Google Scholar] [Publisher Link]
[14] M. Divine et al., “Burkitt Lymphoma in Adults: a Prospective Study of 72 Patients Treated with an Adapted Pediatric LMB Protocol,” Annals of Oncology, vol. 16, no. 12, pp. 1928–1935, 2005.
[CrossRef] [Google Scholar] [Publisher Link]
[15] Robert J Motzer et al., “Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma,” J Clin Oncol, vol. 20, no. 1, pp. 289-96, 2002.
[CrossRef] [Google Scholar] [Publisher Link]
[16] Robert J. Motzer et al., “Prognostic Nomogram for Sunitinib in Patients with Metastatic Renal Cell Carcinoma,” Cancer, vol. 113, no. 7, pp. 1552-1558, 2008.
[CrossRef] [Google Scholar] [Publisher Link]
[17] Saadettin Kılıckap et al., “Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience,” Balkan Medical Journal, vol. 2, pp. 178-85, 2013.
[CrossRef] [Google Scholar] [Publisher Link]
[18] Nicholas C. Denko, “Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour,” Nature Reviews Cancer, vol. 8, pp. 705-713, 2008.
[CrossRef] [Google Scholar] [Publisher Link]
[19] Luca Faloppi et al., “The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Treated with Sorafenib: Implications for Clinical Management,” BMC Cancer, vol. 14, no. 110, pp. 1-8, 2014.
[CrossRef] [Google Scholar] [Publisher Link]
[20] H. Lee, Y. Yuh, and S. Kim, “Serum Lactate Dehydrogenase (LDH) Level as a Prognostic Factor for the Patients with Advanced Gastric Cancer,” Journal of Clinical Oncology, vol. 28, no. 17, pp. 2902-2913, 2009.
[CrossRef] [Google Scholar] [Publisher Link]
[21] Galleze A et al., “Increased Level of Lactate Dehydrogenase Correlates with Disease Growth in Algerian Children with Lymphoma,” Journal of Hematology and Oncology Research, vol. 2, no. 4, pp. 7-15, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[22] Shing Fung Lee, Ting Ying Ng, and Devon Spika, “Prognostic Value of lymphocyte-Monocyte Ratio at Diagnosis in Hodgkin lymphoma: a Meta-Analysis,” BMC Cancer, vol. 19, no. 338, 2019.
[CrossRef] [Google Scholar] [Publisher Link]
[23] Theodoros P. Vassilakopoulos et al., “Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients with Classical Hodgkin Lymphoma Treated with Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens,” The Oncologist, vol. 21, no. 3, pp. 343-353, 2016.
[CrossRef] [Google Scholar] [Publisher Link]